Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
ZAVICEFTA® (ceftazidime-avibactam): Broad-spectrum Gram-negative coverage with consistent dosing across indications1–5
Table 3. Recommended dose for paediatric patients1,5 with estimated CrCL* > 50 mL/min/1.73 m2
When treating for cIAI, cUTI, HAP/VAP or LTO to be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.
When treating for cIAI or LTO, to be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.
Table 3 footnotes:
* CrCL estimated using the Schwartz bedside formula.
¶ The total treatment duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.
ǁ There is very limited experience with the use of ZAVICEFTA for more than 14 days.
**There is limited experience with the use of ZAVICEFTA in paediatric patients 3 months to < 6 month.
Table 4. Great Britain recommended dose for paediatric patients1 with estimated CrCL* ≤ 50 mL/min/1.73 m2
Table 4. Northern Ireland recommended dose for paediatric patients5 with estimated CrCL* ≤ 50 mL/min/1.73 m2
Table 4 footnotes:
*CrCL estimated using the Schwartz beside formula
† Dose recommendations are based on pharmacokinetic modelling. Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only
**Ceftazidime and avibactam are removed by haemodialysis. Dosing of ZAVICEFTA on haemodialysis days should occur after completion of haemodialysis
Table 5. Recommended dose for paediatric patients ≥ 3 months and < 2 years of age1,5 with estimated CrCL* ≤ 50 mL/min/1.73 m2
Table 5 footnotes:
*CrCL estimated using the Schwartz bedside formula
†Dose recommendations are based on pharmacokinetic modelling. Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only
There is insufficient information to recommend a dosage regimen for paediatric patients < 2 years of age that have a CrCL < 16 mL/min/1.73m2
Explore more
Paediatric Tolerability and Efficacy Data
ZAVICEFTA® (ceftazidime-avibactam): For the treatment of adult and paediatric patients aged 3 months and older at high risk of MDR Gram-negative infections1
Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP
REPROVE Phase III trial (HAP and VAP)
Access case studies and videos
Abbreviations
cIAI, complicated intra-abdominal infection; CrCL, creatinine clearance; cUTI, complicated urinary tract infection; ESRD, end stage renal disease; HAP, hospital-acquired pneumonia; LTO, limited treatment options; VAP, ventilator-associated pneumonia; AMR, Antimicrobial Resistance; PK/PD, pharmacokinetics/pharmacodynamics.
Prescribing information
Zavicefta® (ceftazidime and avibactam)
Great Britain
Zavicefta®(ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion
Northern Ireland
Zavicefta®(ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion
Zyvox® (linezolid)
Zyvox (linezolid) 2mg/ml Solution for Infusion
Zyvox (linezolid) 600mg Film-Coated Tablets
Zyvox (linezolid) 100mg/5ml Granules for Oral Suspension
Daptomycin
Great Britain
Daptomycin 350mg Powder for solution for injection/infusion
Daptomycin 500mg Powder for solution for injection/infusion
Northern Ireland
Daptomycin 350 & 500mg powder for solution for injection/infusion
- ZAVICEFTA. Summary of Product Characteristics (Great Britain)
- Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–7
- Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9
- Mazuski JE, et al. Surg Infect 2017;18:1–76
- ZAVICEFTA. Summary of Product Characteristics (Northern Ireland)
Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.
View tolerability profile
Quick Links
Patient Risk Factors
Pathogen Coverage
AMS Resources
PK/PD attributes of ceftazidime–avibactam in patients
Federico Pea, Professor of Pharmacology at the University of Bologna, Italy, presents the 'PK/PD attributes of ceftazidime–avibactam in patients'.
For UK Healthcare Professionals*
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?